ArriVent BioPharma Reports 44.8% Response Rate for ARR-217 in Phase 1 CRC Data

ArriVent BioPharma reported Phase 1 data for ARR-217, showing a 44.8% response rate at 6 mg/kg in pretreated colorectal cancer patients. The disease control rate was 93.1% at this dose. At 4 mg/kg and higher, the response rate was 34.2% with a 91.8% disease control rate. Grade 3 or higher adverse events occurred in 30.1% of patients. The company plans to advance to Phase 1b dose optimization.

Original reporting
Published Oct 26, 2026, 10:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 10:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ArriVent BioPharma Reports 44.8% Response Rate for ARR-217 in Phase 1 CRC Data — source image
Decision brief

The 30-second read

$AVBPBullishHigh
01

Why it matters

The disclosed response rate is substantially higher than typical early‑stage benchmarks, likely prompting short‑term buying interest.

02

Market read

First‑time disclosure of strong Phase 1 efficacy data creates a material news event for AVBP.

03

What to watch

Safety profile beyond Grade 3 events and competitive landscape of colorectal cancer therapies could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

ArriVent BioPharma is a clinical‑stage biotech focused on antibody‑drug conjugates for oncology.

Company-level read

Ticker impact

$AVBPBullishHigh confidence
Context

ArriVent BioPharma disclosed Phase 1 data showing a 44.8% objective response rate for its lead candidate ARR-217 in pretreated colorectal cancer patients.

Expected impact

upward pressure as the market prices in the promising response rate

Evidence & confidence

Phase 1 data with >40% response is unusually high for a colorectal cancer asset, suggesting a meaningful clinical advantage and potential for accelerated development.

Market effects

May boost sentiment toward biotech firms developing oncology immunotherapies.

Limited to U.S. biotech sector; no broader regional effect.

Potentially relevant to global oncology research community but minimal immediate market impact.

Counterpoint

Phase 1 data can be misleading; later‑stage trials may not replicate efficacy, so caution is warranted.

Key entities

  • ArriVent BioPharma Inc.

    Developer of ARR-217, a novel oncology therapeutic.

Related articles

$AVBPHighAI 8/10

ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma (AVBP) reported Q3 2026 results, with R&D expenses at $38.9M and net loss widening to $40.3M. The FURVENT trial missed its primary endpoint, but ALPACCA enrollment continues. ARR-217 showed promising preliminary data, and ARR-002's first-in-human study began. Cash reserves are $393.2M, expected to last until mid-2028. AVBP stock closed at $14.16, up 3.81%.

$AVBPMed

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed

$AVBPMedAI 8/10

Truist raises ArriVent BioPharma stock price target on drug data

Truist raised its price target for ArriVent BioPharma (AVBP) to $21, citing positive early data for ARR-217 in treating metastatic colorectal cancer. The drug showed a 44.8% preliminary response rate and favorable tolerability. Truist expects Phase 1b data in early 2027. AVBP's stock is down 27% from last week, trading at $15.26. Other analysts have mixed views following a Phase 3 trial failure for firmonertinib.

$AVBPMedAI 9/10

ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.